Publications by authors named "S A Fiscus"
Mass surveillance testing can help control outbreaks of infectious diseases such as COVID-19. However, diagnostic test shortages are prevalent globally and continue to occur in the US with the onset of new COVID-19 variants and emerging diseases like monkeypox, demonstrating an unprecedented need for improving our current methods for mass surveillance testing. By targeting surveillance testing toward individuals who are most likely to be infected and, thus, increasing the testing positivity rate (i.
View Article and Find Full Text PDFMass surveillance testing can help control outbreaks of infectious diseases such as COVID-19. However, diagnostic test shortages are prevalent globally and continue to occur in the US with the onset of new COVID-19 variants, demonstrating an unprecedented need for improving our current methods for mass surveillance testing. By targeting surveillance testing towards individuals who are most likely to be infected and, thus, increasing testing positivity rate (i.
View Article and Find Full Text PDFArticle Synopsis
- - The study compared two groups of breastfeeding mothers with HIV: one receiving maternal antiretroviral therapy (mART) and the other receiving infant nevirapine prophylaxis (iNVP), both showing low rates of HIV transmission (<1%).
- - Researchers monitored maternal viral load (MVL) and CD4 cell counts, assessing their impact on infant HIV transmission risk, finding that time-varying MVL and CD4 counts had significant associations with HIV infection risk in the mART group but not in the iNVP group.
- - The results indicate that among mothers on mART, higher MVL and lower CD4 counts during breastfeeding corresponded to a greater risk of transmitting HIV to their infants.
Objectives: The aim of this study was to evaluate penetration of antiretrovirals into compartments and efficacy of a dual, NRTI-sparing regimen in acute HIV infection (AHI).
Design: Single-arm, open-label pilot study of participants with AHI initiating ritonavir-boosted darunavir 800 mg once daily and etravirine 400 mg once daily or 200 mg twice daily within 30 days of AHI diagnosis.
Methods: Efficacy was defined as HIV RNA less than 200 copies/ml by week 24.
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.
J Acquir Immune Defic Syndr
April 2018
Background: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-to-child transmission throughout the breastfeeding period.
Setting: Fourteen sites in Sub-Saharan Africa and India.
Methods: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm (or ≥country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns.